<DOC>
	<DOCNO>NCT00313248</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment new drug call ZK-Epothilone ( ZK-Epo ) patient metastatic breast cancer help decrease stop tumor growth .</brief_summary>
	<brief_title>Evaluation New Agent Treatment Advanced Stage Breast Cancer</brief_title>
	<detailed_description>This study previously register Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc.is sponsor study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Metastatic breast cancer ( mean cancer spread beyond original location ) At least one measurable lesion CT MRI Progression disease follow previous therapy breast cancer Have receive previous treatment anthracyclines ( e.g . doxorubicin [ Adriamycin Doxil ] epirubicin [ Ellence ] ) , taxanes ( paclitaxel [ Taxol Abraxane ] docetaxel [ taxotere ] ) breast cancer Not pregnant Additional criterion determine screen visit . More 3 previous chemotherapy regimens More one treatment non cytotoxic agent breast cancer therapy ( e.g . herceptin [ trastuzumab ] Avastin [ bevacizumab ) Prior treatment epothilones ( e.g . Ixabepilone ) Symptomatic brain metastasis Additional criterion determine screen visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>